Adverse Events of SARS-CoV-2 Therapy: A Pharmacovigilance Study of the FAERS Database

被引:3
|
作者
Pannu, Viraaj [1 ]
Udongwo, Ndausung [1 ]
Imburgio, Steven [1 ]
Johal, Anmol [1 ]
Mararenko, Anton [1 ]
Pozdniakova, Helen [1 ]
Amin, Tasnuva [1 ]
Patel, Swapnil [1 ]
Hossain, Mohammad [1 ]
Mushtaq, Arman [1 ]
Liu, Edward [2 ]
Fune, Jose M. [2 ]
Heaton, Joseph [1 ]
机构
[1] Jersey Shore Univ, Dept Internal Med, Med Ctr, Neptune City, NJ 07753 USA
[2] Jersey Shore Univ, Dept Infect Dis, Med Ctr, Neptune City, NJ 07753 USA
关键词
COVID-19; FAERS; adverse events; antivirals; nirmatrelvir; ritonavir;
D O I
10.1177/10600280231169256
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Over the past 2 years of the several strategies recommended to help fight COVID-19, nirmatrelvir/ritonavir is a novel drug shown in the EPIC-HR phase 2 to 3 clinical trial to lower COVID-19-related death or hospitalization at day 28 when compared with placebo. Objective: Our study's aim was to explore the reported adverse events (AEs) associated with nirmatrelvir/ritonavir use for COVID-19. Method: We conducted a retrospective analysis using the FDA Adverse Event Reporting System (FAERS) database for AEs, listing nirmatrelvir/ritonavir as the primary drug between January and June 2022. The primary outcome was the incidence of reported AEs associated with nirmatrelvir/ritonavir. The OpenFDA database was queried using Python 3.10 to collect the AEs and Stata 17 was used to analyze the database. Adverse events were analyzed by associated medication, with "Covid-19" excluded. Results: A total of 8098 reports were identified between January and June 2022. Most reported complaints in the AE system were COVID-19 and disease recurrence. The most common symptomatic AEs were dysgeusia, diarrhea, cough, fatigue, and headache. Event rates significantly rose between April and May. Disease recurrence and dysgeusia were the most commonly reported complaints for the top 8 concomitant drugs identified. Cardiac arrest, tremor, akathisia, and death were reported in 1, 3, 67, and 5 cases, respectively. Conclusions and Relevance: This is the first retrospective study done on reported AEs associated with nirmatrelvir/ritonavir use for COVID-19. COVID-19 and disease recurrence were the most reported AEs. Further monitoring of the FAERS database is warranted to periodically reassess the safety profile of this medication.
引用
收藏
页码:105 / 109
页数:5
相关论文
共 50 条
  • [31] Assessment of adverse events of tasimelteon: a real-world pharmacovigilance study based on FAERS
    Zuo, Tianqi
    Sun, Shengzhu
    Yang, Jingya
    Wu, Hongyun
    Peng, Wei
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [32] Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database
    Hu, Ye
    Zhang, Linlin
    Gong, Qineng
    Huang, Lei
    Yin, Cunlin
    Miao, Yang
    Wu, Hui
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [33] Adverse events associated with Atogepant: a FAERS-based pharmacovigilance analysis
    Zhang, Ying
    Sun, Shengzhu
    Wang, Yuming
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [34] A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
    Sun, Rui
    Ning, Zhen
    Qin, Henan
    Zhang, Wenhe
    Teng, Yibin
    Jin, Chenxing
    Liu, Jiwei
    Wang, Aman
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [35] Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
    Li, Meng
    Zhang, Qing-Song
    Liu, Xin-Ling
    Wang, Hui-Ling
    Liu, Wei
    PHARMACEUTICALS, 2022, 15 (12)
  • [36] Oral adverse events following immunization against SARS-CoV-2: A case series
    Mahajan, Roopali
    Davila, Andres
    Sollecito, Thomas P. P.
    Stoopler, Eric T. T.
    Kulkarni, Roopali
    ORAL DISEASES, 2024, 30 (03) : 1559 - 1563
  • [37] Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events
    Ng, Siew C.
    Peng, Ye
    Zhang, Lin
    Mok, Chris Kp
    Zhao, Shilin
    Li, Amy
    Ching, Jessica Y. L.
    Liu, Yingzhi
    Yan, Shuai
    Chan, Dream L. S.
    Zhu, Jie
    Chen, Chunke
    Fung, Adrian C. H.
    Wong, Kenneth K. Y.
    Hui, David S. C.
    Chan, Francis K. L.
    Tun, Hein M.
    GUT, 2022, 71 (06) : 1106 - +
  • [38] Frequency of Adverse Events and Relapses after SARS-CoV-2 Vaccination in Patients with Podocytopathies
    Lionaki, Sophia
    Sardeli, Angeliki
    Papasotiriou, Marios
    Dounousi, Evangelia
    Marinaki, Smaragdi
    Pelagia, Kriki
    Gkalitsiou, Dimitra
    Liakopoulos, Vassilios
    Andronikidi, Eva Paraskevi
    Panagiotis, Giannakopoulos
    Panagoutsos, Stylianos A.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [39] SARS-CoV-2, Early Entry Events
    Chambers, James P.
    Yu, Jieh
    Valdes, James J.
    Arulanandam, Bernard P.
    JOURNAL OF PATHOGENS, 2020, 2020
  • [40] Thromboembolic events in patients with SARS-CoV-2
    Ng, Jun Jie
    Choong, Andrew M. T. L.
    JOURNAL OF VASCULAR SURGERY, 2020, 72 (02) : 760 - 761